Scarica l'app Stockscreener
1.95
18.07%
-0.43
Precedente Chiudi:
$2.38
Aprire:
$2.23
Volume 24 ore:
258.32K
Relative Volume:
0.71
Capitalizzazione di mercato:
$4.62M
Reddito:
-
Utile/perdita netta:
$-15.47M
Rapporto P/E:
-2.3214
EPS:
-0.84
Flusso di cassa netto:
$-13.51M
1 W Prestazione:
+2.09%
1M Prestazione:
-40.73%
6M Prestazione:
-73.92%
1 anno Prestazione:
-89.28%
Intervallo 1D:
$1.78
$2.2851
Intervallo di 1 settimana:
$1.73
$2.79
Portata 52W:
$1.73
$24.34
Nls Pharmaceutics Ltd Stock (NLSP) Company Profile
Nome
Nls Pharmaceutics Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta NLSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NLSP
Nls Pharmaceutics Ltd
|
1.95 | 4.62M | 0 | -15.47M | -13.51M | -0.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nls Pharmaceutics Ltd Borsa (NLSP) Ultime notizie
NLS Pharmaceutics and Kadimastem eye January merger - Investing.com
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment - AccessWire
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline By Investing.com - Investing.com South Africa
NLSP Stock Hits 52-Week Low at $1.74 Amid Steep Annual Decline - Investing.com India
NLS Pharmaceutics expects to close Kadimastem merger by end of January - Yahoo Finance
NLSP stock touches 52-week low at $1.81 amid market challenges - Investing.com Nigeria
NLS Pharmaceutics advances in narcolepsy treatment research By Investing.com - Investing.com Nigeria
NLS CEO Highlights Progress on Dual Orexin Agonist Platform and Upcoming Merger - Sleep Review
NLS Pharmaceutics Advances DOXA Platform Amid Merger Plans - TipRanks
NLS Pharmaceutics advances in narcolepsy treatment research - Investing.com India
NLS Pharmaceutics CEO Issues Letter to Shareholders - AccessWire
NLS Pharmaceutics Secures $4.2M Funding, Reports Breakthrough in Narcolepsy Treatment Development - StockTitan
NLS Pharmaceutics AG announced that it expects to receive $0.999998 million in funding - Marketscreener.com
NLS Pharmaceutics sets terms for $1M private placement By Investing.com - Investing.com Canada
NLS Pharmaceutics Offers New Investment Opportunities - TipRanks
NLS Pharmaceutics sets terms for $1M private placement - Investing.com
NLS Pharmaceutics Secures $1M Premium-Priced Private Placement at 15% Above Market - StockTitan
NLS Pharmaceutics reports preclinical data supporting dual orexin receptor agonists - BioWorld Online
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges By Investing.com - Investing.com South Africa
NLS Pharmaceutics reveals promising preclinical data By Investing.com - Investing.com Nigeria
NLS Pharmaceutics reveals promising preclinical data - Investing.com India
NLSP Stock Touches 52-Week Low at $2.98 Amid Market Challenges - Investing.com India
NLS Pharmaceutics announces preclinical data on DOXA platform - TipRanks
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Reports Breakthrough in Sleep-Wake Drug Development | NLSPW Stock News - StockTitan
Preclinical Program Investigates Potential of NLS’ Dual Orexin Agonists for Narcolepsy - Sleep Review
NLS Pharmaceutics highlights preclinical program for AEX-41, AEX-2 - TipRanks
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders - AccessWire
NLS Pharmaceutics Advances Novel Dual Orexin Drug Platform in Key Preclinical Study | NLSPW Stock News - StockTitan
NLS Pharmaceutics AG Announces Share Capital Expansion - TipRanks
ARMISTICE CAPITAL, LLC Acquires Additional Shares in NLS Pharmac - GuruFocus.com
NLS Pharmaceutics announces merger with Kadimastem - Investing.com India
NLSP stock touches 52-week low at $3.15 amid market challenges - Investing.com
500: Something went wrong - Investing.com India
Kadimastem Ltd. Faces Financial Uncertainty - TipRanks
NLS Pharmaceutics Announces Strategic Capital Restructuring - TipRanks
What's Going On With NLS Pharmaceutics Shares Monday? - MSN
NLS and Kadimastem stocks soar following merger agreement - Yahoo Finance
NLS Pharmaceutics and Kadimastem Announce Strategic Merger - TipRanks
NLS Pharmaceutics, Kadimastem enter definitive merger agreement - Yahoo Finance
NLS Pharmaceutics stock jumps 50% on merger agreement with cell therapy firm Kadimastem - MSN
NLS Pharmaceutics and Kadimastem to merge in biotech deal By Investing.com - Investing.com Canada
Definitive Merger Agreement Reached Between NLS and Kadimastem - Sleep Review
NLS Pharmaceutics and Kadimastem to merge in biotech deal - Investing.com India
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement - StreetInsider.com
Nls Pharmaceutics Ltd Azioni (NLSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):